Status:

RECRUITING

Blood Samples for the Study of Peanut, Tree Nut and Other Food Allergies

Lead Sponsor:

University of Colorado, Denver

Collaborating Sponsors:

National Institutes of Health (NIH)

Conditions:

Peanut Allergies

Tree Nut Allergies

Eligibility:

All Genders

1-75 years

Brief Summary

Food allergies are now a major problem. These experiments involve getting blood from people with food allergies and from people without food allergies. The blood collected will be used to answer quest...

Detailed Description

Overview: This is a protocol for obtaining serum, plasma, and cells from subjects with specific food allergies and from controls to be used in studies of peanut and other allergens. We are only asking...

Eligibility Criteria

Inclusion

  • This protocol is to draw blood for a variety of related studies of food allergy. For this reason, we will list each group of subjects and the inclusion criteria for that group.
  • De-identified sera or plasma from patients who have undergone Oral ImmunoTherapy (OIT) for peanut allergy. These samples already exist.
  • Inclusion criteria:
  • patients have been enrolled in a controlled trial of OIT for peanuts, and had at least one oral challenge.
  • Age 1-75.
  • De-identified samples from patients who are undergoing clinically indicated food challenges for peanut allergy.
  • Inclusion criteria:
  • concern regarding possible allergy to peanuts,
  • age 1-75,
  • plan to undergo a clinically indicated challenge with peanuts.
  • Patients with peanut allergy.
  • Inclusion criteria:
  • excellent history of a systemic reaction to peanuts,
  • age 6-75.
  • Patients with other food allergies (especially tree nuts).
  • Inclusion criteria:
  • excellent history of a systemic reaction to tree nuts or other foods,
  • age 6-75.
  • Normal controls.
  • Inclusion criteria:
  • no known food allergies,
  • recent ingestion of peanuts without difficulty, and
  • age 6-75.

Exclusion

  • Any known significant medical or psychiatric diagnosis
  • Use of an investigational drug within 30 days
  • Use of omalizumab (anti-IgE; Xolair) within 6 months

Key Trial Info

Start Date :

February 1 2014

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2030

Estimated Enrollment :

270 Patients enrolled

Trial Details

Trial ID

NCT02192866

Start Date

February 1 2014

End Date

December 1 2030

Last Update

December 19 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Colorado School of Medicine

Denver, Colorado, United States, 80045